By Dorothy Atkins ( October 20, 2017, 4:28 PM EDT) -- The Federal Circuit refused Thursday to toss Mylan's appeal challenging the Patent Trial and Appeal Board's decision to validate a patent for brand-name epilepsy drug Vimpat, rejecting arguments that Mylan can't bring the appeal because it wasn't a party in the underlying inter partes review proceedings....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.